Tim Peara President of Bridge Therapeutics
Bridge Therapeutics, Inc. is a development-stage pharmaceutical company pursuing FDA approval of BT‑219 for Opioid Use Disorder (OUD), and BT-205 for the treatment of chronic pain in opioid experienced patients.